Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
2.56
Times (operating profit in the fiscal year ending March 2029 plan compared with actual results for the fiscal year ending March 2026)Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedNet Sales+86.0%
基準 5,469Target10,175Millions of yen
Operating profit+156.6%
基準 1,559Target4,001Millions of yen
Operating profit margin+10.8pt
基準 28.5Target39.3％
Net income for the current fiscal year+314.9%
基準 619Target2,568Millions of yen
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. For metrics expressed as percentages, differences are shown in percentage points (pt).The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
ROE26.8 ％ → Not disclosed
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planNet Sales 5,087 / Operating profit 1,632 / Net income for the current fiscal year 1,044 → Net Sales 5,469 / Operating profit 1,559 / Net income for the current fiscal year 619（Net Sales Achieved as planned / Operating profit 96% (one year behind schedule) / Net income for the current fiscal year 59% (not achieved)）
Statements about the use of capital
Self-assessment of PBR and share priceAs of the end of March 2026, the market capitalization was ¥14.6 billion, below the ¥25 billion requirement under the Prime Market initial listing criteria. The Company assesses the likelihood of meeting the market capitalization requirement based on the operating profit target for the fiscal year ending March 2028 being 1.87 times that for the fiscal year ending March 2026, assuming that the PER remains at its current level.PBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Focus on the established exhibition and M&A advisory businesses and maximize revenue and profit.
02Restructure and establish the business model of the recruitment support business, centered on the job-hunting event “Growth Job-Hunting DXPO,” to develop it into a third core business after exhibitions and M&A brokerage.
03Growth strategy 1: Develop deeper, industry-specific offerings
04Growth strategy 2: Expand horizontally into other industries
Plan assumptionsTarget an average annual increase in net sales of 23% over the three-year period, Target an average annual increase in profit of 37% over the three-year period, For the market capitalization requirement, assume that the PER remains at its current level
Segment targetSegment Exhibition business / Target fiscal year Fiscal year ending March 2029 / Sales Target 5,089 Millions of yen / Profit Target Not disclosed, Segment Exhibition business, nursing care sector / Target fiscal year Fiscal year ending March 2029 / Sales Target 1,508 Millions of yen / Profit Target Not disclosed, Segment Exhibition business, IT sector / Target fiscal year Fiscal year ending March 2029 / Sales Target 2,962 Millions of yen / Profit Target Not disclosed
Non-financial targetsIndicator Shareholders / Target value 800 or more / Timing End of the fiscal year ending March 2028, Indicator Tradable share ratio / Target value 35% or more / Timing End of the fiscal year ending March 2028
Size of the Target MarketThe normal market size of the exhibition business is approximately ¥160 billion, leaving room to expand sales by ¥16 billion to ¥32 billion if a market share of 10% to 20% is achieved in the future. The potential for expansion of the M&A business in the nursing care sector is ¥10 billion to ¥12 billion. Sources cited include Dentsu Inc., “Advertising Expenditures in Japan in 2020”; BOP Inc., “Comprehensive Handbook of Trade Fairs and Exhibitions”; Tokyo Shoko Research; the Tokyo Metropolitan Bureau of Social Welfare and Public Health; and the Ministry of Health, Labour and Welfare.
Reason for revision or withdrawal
If progress continues in line with the second medium-term plan, the Company is expected to meet all of the Prime Market initial listing criteria in the fiscal year ending March 2028. Accordingly, the Prime Market listing has been postponed by one year, with the fiscal year ending March 2028 designated as the reference fiscal year.
| Item | Details |
|---|---|
| Plan name | Second Medium-Term Plan “Vision2029” |
| Plan period | FY ending March 2027–FY ending March 2029 |
| Progress against the plan | Formulated |
| Sales Target | 5,469 Millions of yen → 10,175 Millions of yen（1.86 times (compared with the fiscal year ending March 2026)） |
| Operating profit target | 1,559 Millions of yen → 4,001 Millions of yen（2.56 times (compared with the fiscal year ending March 2026)） |
| Operating profit margin target | 28.5 ％ → 39.3 ％ |
| Net income target | 619 Millions of yen → 2,568 Millions of yen |
| ROE target | 26.8 ％ → Not disclosed |
| Self-assessment of PBR and share price | As of the end of March 2026, the market capitalization was ¥14.6 billion, below the ¥25 billion requirement under the Prime Market initial listing criteria. The Company assesses the likelihood of meeting the market capitalization requirement based on the operating profit target for the fiscal year ending March 2028 being 1.87 times that for the fiscal year ending March 2026, assuming that the PER remains at its current level. |
| Segment target | Segment Exhibition business / Target fiscal year Fiscal year ending March 2029 / Sales Target 5,089 Millions of yen / Profit Target Not disclosed, Segment Exhibition business, nursing care sector / Target fiscal year Fiscal year ending March 2029 / Sales Target 1,508 Millions of yen / Profit Target Not disclosed, Segment Exhibition business, IT sector / Target fiscal year Fiscal year ending March 2029 / Sales Target 2,962 Millions of yen / Profit Target Not disclosed |
| Non-financial targets | Indicator Shareholders / Target value 800 or more / Timing End of the fiscal year ending March 2028, Indicator Tradable share ratio / Target value 35% or more / Timing End of the fiscal year ending March 2028 |
| Plan assumptions | Target an average annual increase in net sales of 23% over the three-year period, Target an average annual increase in profit of 37% over the three-year period, For the market capitalization requirement, assume that the PER remains at its current level |
| Key initiatives | Focus on the established exhibition and M&A advisory businesses and maximize revenue and profit., Restructure and establish the business model of the recruitment support business, centered on the job-hunting event “Growth Job-Hunting DXPO,” to develop it into a third core business after exhibitions and M&A brokerage., Growth strategy 1: Develop deeper, industry-specific offerings, Growth strategy 2: Expand horizontally into other industries |
| Results under the previous plan | Net Sales 5,087 / Operating profit 1,632 / Net income for the current fiscal year 1,044 → Net Sales 5,469 / Operating profit 1,559 / Net income for the current fiscal year 619（Net Sales Achieved as planned / Operating profit 96% (one year behind schedule) / Net income for the current fiscal year 59% (not achieved)） |
| Reason for revision or withdrawal | If progress continues in line with the second medium-term plan, the Company is expected to meet all of the Prime Market initial listing criteria in the fiscal year ending March 2028. Accordingly, the Prime Market listing has been postponed by one year, with the fiscal year ending March 2028 designated as the reference fiscal year. |
| Size of the Target Market | The normal market size of the exhibition business is approximately ¥160 billion, leaving room to expand sales by ¥16 billion to ¥32 billion if a market share of 10% to 20% is achieved in the future. The potential for expansion of the M&A business in the nursing care sector is ¥10 billion to ¥12 billion. Sources cited include Dentsu Inc., “Advertising Expenditures in Japan in 2020”; BOP Inc., “Comprehensive Handbook of Trade Fairs and Exhibitions”; Tokyo Shoko Research; the Tokyo Metropolitan Bureau of Social Welfare and Public Health; and the Ministry of Health, Labour and Welfare. |
| Publication date | 13 May 2026 |
Items this document does not state (8)
ROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalTotal investment planInvestment amount by sectorRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.If progress continues in line with the second medium-term plan, the Company is expected to meet all of the Prime Market initial listing criteria in the fiscal year ending March 2028. Accordingly, the Prime Market listing has been postponed by one year, with the fiscal year ending March 2028 designated as the reference fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.